Michael Bitzer

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction

M. Stahl, Martin K. Walz, Martin Stuschke et al. · Journal of Clinical Oncology · 2009 · 951 citations

Medicine, Oncology, Surgery +17

Swarm Learning for decentralized and confidential clinical machine learning

Stefanie Warnat‐Herresthal, Hartmut Schultze, Krishnaprasad Lingadahalli Shastry et al. · Nature · 2021 · 838 citations · Full text

Computing, Biomedical Informatics, Health Informatics +13

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 425 citations

Medicine, Oncology, Cancer Pharmacology +13

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12